<DOC>
	<DOCNO>NCT01975090</DOCNO>
	<brief_summary>The SENTRY Bioconvertible Inferior Vena Cava ( IVC ) Filter develop provide temporary protection pulmonary embolism ( PE ) .</brief_summary>
	<brief_title>The SENTRY Clinical Study</brief_title>
	<detailed_description>Pulmonary embolism ( PE ) prevalent disease significant morbidity mortality . The estimated annual incidence 1.45 per 1,000 patient , translate 1,350,000 case per year United States . It estimate PE result 200,000 death per year . Currently two type commercially available IVC filter utilized prevent PE ; permanent retrievable . Both type filter document limitation , tilting , migration , fracture , embolization late deep vein thrombosis ( DVT ) . Retrievable filter develop avert late consequence permanent filter , practice low success eventual removal . In series 37 clinical study , total 6,834 patient mean retrieval rate 34 % . There numerous design feature SENTRY IVC Filter intend improve limitation available IVC filter obviate need retrieval .</detailed_description>
	<mesh_term>Thrombosis</mesh_term>
	<mesh_term>Embolism</mesh_term>
	<mesh_term>Pulmonary Embolism</mesh_term>
	<mesh_term>Venous Thrombosis</mesh_term>
	<criteria>1 . &gt; 18 year age 2. fully inform subject execute Institutional Review Board ( IRB ) Ethics Committee ( EC ) approve informed consent 3. willing able comply followup visit requirement 4. requirement transient PE protection &lt; 60 day 5. documented high risk PE DVT 6. inability use anticoagulation due contraindication , failure , complication risk injury pharmacotherapy 7 . IVC diameter compatible filter diameter 8 . IVC length adequate filter placement 1. intellectual impairment prevent understanding involvement clinical study 2. hypersensitivity device component 3. impaired renal function define serum creatinine level &gt; 2.0 mg/dL 4. active systemic infection 5. life expectancy &lt; 12 month 6. malignancy extend PE risk &gt; 60 day 7. pregnant plan become pregnant study followup period 8. participate another investigational trial reach primary endpoint 9. know hypercoaguable state 10. inherit acquire hemostatic disorder 11. history presence caval stent filter 12. inability gain femoral jugular access 13. duplicate left side IVC 14. renal vein thrombosis IVC thrombosis extend renal vein 15. jugular femoral vein irregularity , stenosis aneurysm would interfere successful device delivery 16. spinal irregularity may interfere successful device delivery 17. occlusive freefloating thrombus IVC 18. contrast allergy adequately premedicated</criteria>
	<gender>All</gender>
	<minimum_age>18 Years</minimum_age>
	<maximum_age>N/A</maximum_age>
	<verification_date>October 2016</verification_date>
</DOC>